Illidge, T, Pro, B, Trumper, L, O'Connor, O A, Advani, R, Iyer, S, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Zinzani, P-L, Little, M, Manley, T, Rao, S, Fanale, M & Horwitz, S 2019, ' The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas ', 24th European Hematology Association Congress (EHA), Amsterdam, Netherlands, 13/06/2019-16/06/2019 . < https://library.ehaweb.org/eha/2019/24th/266687/tim.illidge.the.echelon-2.trial.results.of.a.randomized.double-blind.phase.3.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dps1070 >